Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748076 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3673905 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3748046 | 0.88 | C5AR1 (0.52) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL1834216 | 0.88 | CYP3A4 (0.45) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3639898 | 0.88 | C5AR1 (0.52) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL1834213 | 0.88 | CYP3A4 (0.45) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3744564 | 0.85 | CACNA1G (0.41) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3749278 | 0.85 | CACNA1G (0.41) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3749275 | 0.85 | CACNA1G (0.41) | CYP3A4CYP2D6C5AR1CACNA1GCACNA1H | |
| SCHEMBL3745839 | 0.84 | SMN1; SMN2 (0.38) | CYP3A4CYP2D6CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | claimed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | CYP3A4 694/4885CYP2D6 873/4885C5AR1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.